Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial
The DOI matches its Crossref record.
Abstract
BACKGROUND: Recently, the serotonin antagonist ondansetron has been reported to have a positive effect on cholestasis-associated pruritus. OBJECTIVES: To study the effect of orally administered ondansetron on pruritus in chronic liver disease in a randomized, placebo-controlled, double-blind, cross-over study. METHODS: Subjective severity of pruritus was assessed using a visual analogue scale (VAS) recorded four times daily by the patients. After a one week pretreatment baseline period the patients were randomized to receive ondansetron tablets 8 mg tds or placebo tablets tds for one week. Following a one week wash-out period patients were switched to the other treatment for one week. The study was ended by an additional follow-up week without medication. For each day peak VAS values were determined and the mean value of the last five days of each week was calculated and referred to as the composite peak VAS score. RESULTS: We observed a significant but moderate reduction of the composite peak VAS score of 1.34 points (CI(95%): 0.12-2.56; P=0.033) during treatment with ondansetron as compared to placebo (treatment effect). In addition, a period effect was observed: a reduction of composite peak VAS score by 1.26 points (C1(95%): 0.04-2.48; P=0.044) was seen in the second treatment period as compared to the first period, irrespective of the kind of treatment. Although under treatment with ondansetron a significant improvement of itching as assessed by the VAS score was demonstrated, this treatment was not preferred over placebo by the patients. CONCLUSIONS: The 5-hydroxytryptamine receptor type 3 antagonist ondansetron has a small, but significant positive effect on pruritus in chronic liver disease as compared to placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Itch: scratching more than the surface
Twycross, R. (2003) · QJM · doi:10.1093/qjmed/hcg002 · Cited by 407
European S2k Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Dalgard, F., Garcovich, S., Gieler, U., Giménez-Arnau, A., Lambert, J., Leslie, T., Mettang, T., Misery, L., et al. (2019) · Acta Dermato Venereologica · doi:10.2340/00015555-3164 · Cited by 405
European Guideline on Chronic Pruritus
Weisshaar, E., Szepietowski, J., Darsow, U., Misery, L., Wallengren, J., Mettang, T., Gieler, U., Lotti, T., Lambert, J., Maisel, P., et al. (2012) · Acta Dermato Venereologica · doi:10.2340/00015555-1400 · Cited by 253
Jones, A. E., & Bergasa, N. V. (1999) · Hepatology · doi:10.1002/hep.510290450 · Cited by 202
“[106] Muller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, et al.”
BackgroundOndansetron: A Selective 5‐HT3Receptor Antagonist and Its Applications in CNS‐Related Disorders
Ye, J., Ponnudurai, R., & Schaefer, R. (2001) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2001.tb00195.x · Cited by 162
Metadata
- Authors
- Müller, C., Pongratz, S., Pidlich, J., Penner, E., Kaider, A., Schemper, M., Raderer, M., Scheithauer, W., & Ferenci, P.
- Venue
- European Journal of Gastroenterology & Hepatology
- Published
- 1998-10
- Volume
- 10
- Issue
- 10
- Pages
- 865-870
- ISSN
- 0954-691X (ISSN-L)
- OpenAlex
- W2059129451
- Cited by
- 119
- References
- 0
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. https://app.cochat.ai/papers/10.1097/00042737-199810000-00010
- The paper
- Müller, C., Pongratz, S., Pidlich, J., Penner, E., Kaider, A., Schemper, M., Raderer, M., Scheithauer, W., & Ferenci, P. (1998). Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. European Journal of Gastroenterology & Hepatology. https://doi.org/10.1097/00042737-199810000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.